Novel Immunotherapy Tebentafusp Granted Fast Track Designation for Metastatic Uveal Melanoma

Source: Targeted Oncology, May 2019

The FDA has granted tebentafusp (IMCgp100) a fast track designation for the treatment of patients with HLA-A*0201-positive previously untreated metastatic uveal melanoma, according to Immunocore Limited, the company developing the novel immunotherapy agent.

In findings from a phase I study, tebentafusp demonstrated an overall survival (OS) rate of 74% at 1 year in patients with heavily pretreated metastatic uveal melanoma. At a median follow-up of 15.9 months, the median OS had not yet been reached.

Sixty-six percent of patients (95% CI, 39%-83%) remained alive and progression-free at 1 year by immune-related response criteria.

read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder